NCT02716272View on ClinicalTrials.gov

Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

March 24, 2016

Primary Completion Date

February 28, 2018

Study Completion Date

June 22, 2019

Conditions
Mesothelioma
Interventions
DRUG

Nivolumab

Nivolumab administered IV over 60 minutes at 3mg/kg every 2 weeks

DRUG

Nivolumab + Ipilimumab

Nivolumab administered IV over 60 minutes at 3mg/kg every 2 weeks, combined with Ipilimumab administered IV over 90 minutes at 1mg/Kg every 6 weeks

Trial Locations (22)

38000

Grenoble - CHU, Grenoble

49000

Angers - CHU, Angers

63000

Dijon - CHU, Dijon

68000

Mulhouse - CH, Mulhouse

69495

HCL Lyon Sud, Pierre-Bénite

72000

Centre Hospitalier - Pneumologie, Le Mans

75020

AP-HP Hopital Tenon - Pneumologie, Paris

76000

Rouen - CHU, Rouen

76600

Centre Hospitalier - Pneumologie, Le Havre

83000

Toulon - CHI, Toulon

84918

Avignon - Institut Sainte-Catherine, Avignon

94800

Gustave Roussy, Villejuif

Unknown

CHU, Clermont-Ferrand

CHRU Lille - Hopital Calmette, Lille

AP-HM Hôpital Nord, Marseille

AP-HP Hôpital Bichat, Paris

Pontoise - CH, Pontoise

Rennes - CHU, Rennes

Centre Etienne Dolet, Saint-Nazaire

CHU Strasbourg, Strasbourg

Toulouse - CHU Larrey, Toulouse

CHU Tours - Pneumologie, Tours

All Listed Sponsors
lead

Intergroupe Francophone de Cancerologie Thoracique

OTHER

NCT02716272 - Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients | Biotech Hunter | Biotech Hunter